115 related articles for article (PubMed ID: 37268188)
1. Should Redo Surgery be Offered to Patients with Relapsed Glioblastoma? - Outcome Analyses of a Single Institution Comparative Cohort Study.
Eltoukhy M; Kandula V; Joseph S; Albanese E; Giridharan S
World Neurosurg; 2023 Aug; 176():e543-e547. PubMed ID: 37268188
[TBL] [Abstract][Full Text] [Related]
2. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
3. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
[TBL] [Abstract][Full Text] [Related]
4. Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma.
Fathi Kazerooni A; Akbari H; Shukla G; Badve C; Rudie JD; Sako C; Rathore S; Bakas S; Pati S; Singh A; Bergman M; Ha SM; Kontos D; Nasrallah M; Bagley SJ; Lustig RA; O'Rourke DM; Sloan AE; Barnholtz-Sloan JS; Mohan S; Bilello M; Davatzikos C
JCO Clin Cancer Inform; 2020 Mar; 4():234-244. PubMed ID: 32191542
[TBL] [Abstract][Full Text] [Related]
5. Surgery for Recurrent Glioblastoma Multiforme: A Retrospective Case Control Study.
Voisin MR; Zuccato JA; Wang JZ; Zadeh G
World Neurosurg; 2022 Oct; 166():e624-e631. PubMed ID: 35870781
[TBL] [Abstract][Full Text] [Related]
6. Fluorescein Sodium in the Surgical Treatment of Recurrent Glioblastoma Multiforme.
Höhne J; Schebesch KM; de Laurentis C; Akçakaya MO; Pedersen CB; Brawanski A; Poulsen FR; Kiris T; Cavallo C; Broggi M; Ferroli P; Acerbi F
World Neurosurg; 2019 May; 125():e158-e164. PubMed ID: 30682505
[TBL] [Abstract][Full Text] [Related]
7. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
Li YM; Suki D; Hess K; Sawaya R
J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
[TBL] [Abstract][Full Text] [Related]
8. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme: A Retrospective Multi-Institutional Experience.
Lovo EE; Moreira A; Barahona KC; Ramirez J; Campos F; Tobar C; Caceros V; Sallabanda M; Sallabanda K
Cureus; 2021 Oct; 13(10):e18480. PubMed ID: 34754642
[TBL] [Abstract][Full Text] [Related]
10. The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma.
D'Amico RS; Cloney MB; Sonabend AM; Zacharia B; Nazarian MN; Iwamoto FM; Sisti MB; Bruce JN; McKhann GM
World Neurosurg; 2015 Oct; 84(4):913-9. PubMed ID: 26074434
[TBL] [Abstract][Full Text] [Related]
11. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
12. Impact of resection on overall survival of recurrent Glioblastoma in elderly patients.
Hager J; Herrmann E; Kammerer S; Dinc N; Won SY; Senft C; Seifert V; Marquardt G; Quick-Weller J
Clin Neurol Neurosurg; 2018 Nov; 174():21-25. PubMed ID: 30195896
[TBL] [Abstract][Full Text] [Related]
13. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
Suchorska B; Weller M; Tabatabai G; Senft C; Hau P; Sabel MC; Herrlinger U; Ketter R; Schlegel U; Marosi C; Reifenberger G; Wick W; Tonn JC; Wirsching HG
Neuro Oncol; 2016 Apr; 18(4):549-56. PubMed ID: 26823503
[TBL] [Abstract][Full Text] [Related]
14. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
Azoulay M; Santos F; Shenouda G; Petrecca K; Oweida A; Guiot MC; Owen S; Panet-Raymond V; Souhami L; Abdulkarim BS
J Neurooncol; 2017 May; 132(3):419-426. PubMed ID: 28374095
[TBL] [Abstract][Full Text] [Related]
15. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
17. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
Hong B; Wiese B; Bremer M; Heissler HE; Heidenreich F; Krauss JK; Nakamura M
Am J Clin Oncol; 2013 Jun; 36(3):261-8. PubMed ID: 22495452
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of Repeat Awake Craniotomy: A Propensity-Score-Matched Analysis on 607 Consecutive Cases.
Takami H; Venkatraghavan L; Chowdhury T; Bernstein M
World Neurosurg; 2022 Nov; 167():e922-e928. PubMed ID: 36113715
[TBL] [Abstract][Full Text] [Related]
19. Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit.
Fariña Nuñez MT; Franco P; Cipriani D; Neidert N; Behringer SP; Mader I; Delev D; Fung C; Beck J; Sankowski R; Nicolay NH; Heiland DH; Schnell O
J Neurooncol; 2020 Jan; 146(2):381-387. PubMed ID: 31933259
[TBL] [Abstract][Full Text] [Related]
20. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
Piccioni DE; Selfridge J; Mody RR; Chowdhury R; Li S; Lalezari S; Wawrzynski J; Quan J; Zurayk M; Chou AP; Sanchez DE; Liau LM; Ellingson BM; Pope WB; Nghiemphu PL; Green RM; Wang HJ; Yong WH; Elashoff R; Cloughesy TF; Lai A
Neuro Oncol; 2014 Jun; 16(6):815-22. PubMed ID: 24627236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
